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ABSTRACT
Objective: The purpose of this study was to determine the compliance rate with a maternal risk-
factor-based guideline for the prevention of neonatal group B streptococcal (GBS) sepsis.
Methods: In August 1994, a risk-factor-based guideline for selective intrapartum prophylaxis
against neonatal GBS was adopted by a group model health maintenance organization. This guide-
line identified the following maternal risk factors for neonatal GBS sepsis: preterm delivery, rupture
of membranes for >18 h, fever/chorioamnionitis, and history of a previous GBS-affected child.
Patients with one or more risk factors were to receive intrapartum antibiotic prophylaxis consisting
of either ampicillin, erythromycin, or clindamycin. We conducted a retrospective chart review to
record risk factors and use of antibiotics. We hypothesized that >90% of patients with risk factors
would receive intrapartum chemoprophylaxis.
Results: A total of 805 maternal charts were reviewed. Of these, 105 (13%) were candidates for
intrapartum prophylaxis. We found an overall compliance rate of 65%. Compliance rates by risk
factor were preterm delivery (51%), prolonged rupture of membranes (73%), fever/chorioamnio-
nitis (87%), and previous affected child (100%).
Conclusions: Our results show unexpectedly low compliance rates with a risk-factor-based guide-
line for the prevention of neonatal GBS sepsis. Only 65% of women with any risk factor for
neonatal GBS sepsis received intrapartum antibiotic prophylaxis appropriately. Educational efforts
to improve compliance with a risk-factor-based guideline should specifically address mothers de-
livering at 34-36 weeks gestation and mothers with prolonged rupture of membranes. Infect. Dis.
Obstet. Gynecol. 5:345-348, 1997. (C) 1998 Wiley-Liss, Inc.
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he best strategy to prevent early-onset neona-
tal group B streptococcal (GBS) sepsis is con-
troversial. During the past 2 decades, investigators
have proposed several options including 1) ante-
partum treatment ofwomen known to be colonized
with GBS, 2) intrapartum chemoprophylaxis to ei-
ther culture-positive women or women with known
risk factors, 3) early administration of penicillin to
all neonates, and 4) universal immunization of all
pregnant women. Clinical trials have demonstrated
that intrapartum prophylaxis is effective for pre-
vention of neonatal GBS sepsis. 1-7 Until mid-1996,
consensus regarding the optimum protocol had not
yet been reached between the Centers for Disease
Control and Prevention (CDC), the American
Academy of Pediatrics (AAP), and the American
College of Obstetricians and Gynecologists (ACOG).
The differing positions of these organizations re-
flect practical concerns regarding feasibility, effi-
cacy, and cost-effectiveness.
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Compliance limits the success of any protocol.
Complex protocols may have a low compliance
rate. Gibbs et al.8 implemented a guideline in a
university hospital setting in which they cultured
all women for GBS at 26-28 weeks gestation and
treated intrapartum those women who were GBS
positive and had risk factors. Over 2 years, the com-
pliance rate was 80%. There were 5 cases of neo-
natal GBS sepsis which were associated with either
protocol violations, protocol failures, or both. We
implemented a guideline based solely on maternal
risk factors in a health maintenance organization
(HMO) setting. We hypothesized that this simpler
protocol would have a 90% compliance rate.
METHODS
In August 1994, the Department of Obstetrics and
Gynecology at Kaiser Permanente, a group model
HMO in Denver, CO, adopted a guideline for the
prevention of early-onset neonatal GBS sepsis.
This guideline was adapted from AGOG guide-
lines9 and identified the following as maternal risk
factors for neonatal GBS sepsis: preterm delivery
(<37 weeks), rupture of membranes >18 h, mater-
nal fever in labor (>38C) accompanied by clinical
signs of intraamniotic infection, and previous child
affected by GBS. Kaiser Permanente patients de-
liver at one of two area hospitals and over 90%
deliver at St. Joseph Hospital in Denver, CO. Care
of these patients is provided by Kaiser Permanente
attending obstetricians and by St. Joseph Hospital
obstetrical and family practice house staff. All pa-
tients with one or more risk factors were to receive
intrapartum antibiotic prophylaxis consisting of
ampicillin 2 g intravenously every 6 h until delivery
or, if allergic to penicillin, erythromycin 500 mg
intravenously every 6 h or clindamycin 900 mg in-
travenously every 8 h. Cultures for GBS were not
collected unless the patient presented with pre-
term premature rupture of membranes (PPROM).
All women at their initial obstetrical visit under-
went urinary screening with a dipstick. Positive
screening was defined as the presence of nitrites or
leukocytes on dipstick, or >10 WBC/hpf or 3+ bac-
teria on microscopic examination. Patients who had
positive screening had urinary cultures performed.
Women with urinary cultures positive for GBS
were treated and were not included in this guide-
line for prophylaxis. During this time period, pa-
tients with idiopathic preterm labor unlikely to de-
liver and patients with PPROM not in labor were
not routinely treated with antibiotics.
Implementation of this risk-factor-based proto-
col was assisted with educational conferences pro-
vided to all attending obstetricians, house staff, and
nurses involved with direct patient care of laboring
patients. Copies of the guidelines were posted in
the labor and delivery suites and provided to all
involved personnel. Standing orders included noti-
fication of physicians by the nursing staff when
women were <37 weeks gestational age or had rup-
ture of membranes for >18 h.
We retrospectively reviewed charts of all Kaiser
Permanente patients delivering at St. Joseph Hos-
pital between January 1, 1995, and March 31, 1995.
We identified these patients by an existing perina-
tal data base. Since we hypothesized that compli-
ance would be 90%, a 3 month sample of delivering
mothers was determined to have 80% power to de-
tect a difference in compliance of 10%. We ex-
cluded patients with deliveries before 24 weeks of
gestation or with a fetal demise at any gestational
age. We reviewed charts, using a standard form, for
gravidity, parity, gestational age at delivery, pres-
ence of risk factors, and administration of intrave-
nous antibiotics. Documentation of antibiotic ad-
ministration was obtained from the nursing record
and not from physician orders. Charts with missing
values or those showing non-compliance with the
protocol, i.e., no antibiotics given to a patient with
a risk factor, were re-audited by two investigators.
We compared the overall compliance rate with the
anticipated rate by the chi-square test and consid-
ered P < 0.05 to be significant.
RESULTS
A total of 805 maternal charts were reviewed. We
could not locate 4 charts of patients delivering dur-
ing this time period. Of these patients, 105 (13%)
were candidates for intrapartum prophylaxis be-
cause of maternal risk factors. Sixty-eight of these
patients received antibiotic prophylaxis for an over-
all compliance rate of 65% (P < 0.001, compared to
predicted value). Compliance rates by risk factor
are listed in Table 1.
We observed a preterm delivery rate of 6% (51
of 805). For women with preterm delivery, the
compliance rate was 51% (26 of 51). This group had
the lowest compliance rate in this study. Of the
patients with preterm delivery who failed to re-
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TABLE I. Maternal risk factors for neonatal GBS
sepsis by prevalence and compliance rate
Risk factor Compliance
Risk factor prevalence rate
Preterm delivery 51/805 (6%) 26/51 (5 I%)
Rupture of membranes >18 h 37/805 (5%) 27/37 (73%)
Fever/chorioamnionitis 30/805 (4%) 26/30 (87%)
Previous affected child 3/805 (0.4%) 3/3 (100%)
Any risk factor 105/805 (I 3%) 68/105 (65%)
aCompliance is defined as administration of appropriate antibiotics after
identification of appropriate risk factors.
ceive intrapartum antibiotic prophylaxis, all were
between 34 and 36 weeks of gestation.
We found prolonged rupture of membranes in
5% (37 of 805)of women. For these, the compli-
ance rate was 73% (27 or 37). Of the non-compliant
cases, 6 of 10 (60%) had a duration of rupture of
membranes between 18 and 19 h and 9 of 10 (90%)
had a duration of rupture of <24 h. There were 3
patients with a previous child affected by GBS; all
of these received intrapartum antibiotics. Of 5
women with a positive urinary or genital GBS cul-
ture, 4 received intrapartum prophylaxis in the ab-
sence of other specified risk factors.
Two neonates during the study period were
treated after birth for blood culture positive GBS
sepsis. Neither mother received intrapartum anti-
biotic therapy nor had any risk factor. One mother
underwent induction at 40 weeks of gestation for a
low amniotic fluid index. She received two prosta-
glandin suppositories and oxytocin and delivered
within 14 h after placement of the first suppository.
Membranes were ruptured 3 h before delivery, and
the mother was afebrile during her labor. The neo-
nate was admitted to the neonatal intensive care
unit (NICU) for hypoglycemia and blood cultures
were subsequently positive for GBS. The second
patient labored spontaneously at 40 weeks of ges-
tation. Membranes were ruptured for 8 h prior to
delivery and the mother was afebrile during her
labor. After a forceps delivery, the baby was taken
to the NICU for presumptive meconium aspira-
tion. Both babies were discharged within 14 days of
delivery, received home intravenous antibiotic
therapy, and recovered without sequelae.
DISCUSSION
We found that compliance with this risk-factor-
based guideline for the prevention of neonatal GBS
sepsis was lower than predicted (65% vs. 90%).
This lower rate was due largely to non-compliance
in two risk factor categories: delivery before 37
weeks gestation and rupture of membranes longer
than 18 h. For the former, all cases of non-
compliance occurred between 34 and 36 weeks of
gestation. For prolonged rupture of membranes,
90% (9 of 10) of guideline violations occurred when
time from rupture to delivery was between 18 and
24 h.
We offer several explanations for the lower com-
pliance with this guideline in these two risk factor
categories. First, tocolysis is controversial at 36-37
weeks of gestation and these mothers may not have
been labeled "preterm." Also, several patients in
this risk factor category were induced for pre-
eclampsia, and the clinicians involved with their
care may have focused more on hypertension than
prematurity, thus failing to identify these women
as candidates for intrapartum prophylaxis. Second,
some women experienced a rapid labor, and there
may not have been time to administer chemopro-
phylaxis. Historically, clinicians have been taught
to have increased suspicion for chorioamnionitis
starting at 24 h after rupture of membranes. Start-
ing antibiotic therapy at 18 h may represent a
change in practice and patients at 18 h may not
have been identified as being at risk. An additional
factor was the number of physicians involved.
Nearly 40 physicians rotated in attendance at these
births. Finally, even the use of "standard" written
orders to notify physicians in situations when GBS
prophylaxis is indicated did not prevent protocol
violations. This may reflect the use of verbal orders
on labor and delivery. Educational efforts aimed at
improving identification of appropriate candidates,
particularly those with gestational age of 34-36
weeks and rupture of membranes between 18 and
24 h, might improve compliance considerably.
In programs that culture all pregnant women for
GBS and treat those women who test positive, the
rate of intrapartum chemoprophylaxis may be as
high as 40%.l There is concern that chemoprophy-
laxis of a high percentage of women in labor will
result in the selection of antibiotic-resistant bacte-
ria strains. In this risk-factor-based guideline, 13%
(105/805) of the population were candidates for in-
trapartum chemoprophylaxis. This is less than the
18% predicted by Rouse et al., 11 who used a deci-
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sion analysis to compare rates of chemoprophylaxis
using culture vs. risk-factor-based guidelines.
The CDC recently published guidelines that of-
fer a choice between risk-factor-based and mixed
risk-factor/culture-based guidelines for intrapartum
chemoprophylaxis, lz The decision on which guide-
line to use should be based not only on rates of
GBS carriage, incidence of neonatal sepsis, and risk
factors, but also on practical concerns including
compliance. Although this risk-factor-based guide-
line did not eliminate neonatal GBS sepsis, it did
address those infants most likely to experience the
greatest morbidity and mortality while prophylax-
ing a reasonable percentage of women (13%). Suc-
cessful implementation of guidelines requires edu-
cation, provider feedback, and evaluation of the
contribution to health care. Educational efforts
which target the risk factors of preterm delivery
and premature rupture of membranes may improve
compliance with this guideline.
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